Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) does about 856.74K shares in volume on a normal day but saw 1431097 shares change hands in Friday trading. The company now has a market cap of 1.43B USD and an enterprise value of about $1.30B. Its current market price is $62.65, marking an increase of 6.55% compared to the previous close of $58.80. The 52 week high reached by this stock is $63.45 whilst the lowest price level in 52 weeks is $8.51. The script in recent trading has seen the stock touch a high of $66.24 and a low of $59.75.
Arcturus Therapeutics Holdings Inc. (ARCT) has a 20-day trading average at $54.91 and the current price is -1.26% off the 52-week high compared with 636.19% distance from its 52-week low. The 50-day simple moving average of the closing price is $50.86 and its 200-day simple moving average is $26.78. If we look at the stock’s price movements over the week, volatility stands at 9.15%, which increases to 9.23% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 62.06 to suggest the stock is neutral.
10 analysts observing the Arcturus Therapeutics Holdings Inc. (ARCT) stock have set the 12-month price targets for the company’s shares at between $31.00 and $82.00. The consensus objective for the share price is $66.64, suggesting that the stock has a potential upside of 5.99% over the period. The median price target is 19.16% away from the current levels at $77.50.
FactSet Research has provided data showing that 10 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 2 advise that it is a overweight. 7 analysts have rated it as a buy and 1 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Strong Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on July 30, 2020 when ROTH Capital resumed the stock to “Buy” and issued a price target of $77.
The current price level is 15.02%, 24.64%, and 136.21% away from its SMA20, SMA50, and SMA200 respectively, with the ARCT price moving above the 50-day SMA on August 21. Arcturus Therapeutics Holdings Inc. (ARCT) stock is up 29.93% over the week and 14.70% over the past month. Its price is 476.36% year-to-date and 474.77% over the past year.
The stock last released its quarterly earnings report for quarter ended 6/29/2020, with the company’s earnings per share (EPS) of -$0.55 below consensus estimates by $0. ARCT’s earnings per share are forecast to grow by 0.90% this year and 113.60% over next year. Expected sales for next quarter are $3.17 million, which analysts say will come at $11.26 million for the current fiscal year and next year at $151.27 million. In addition, estimates put the company’s current quarterly revenue at an average of $3.01 million.
Its 12-month price target is $77.50. To reach the target analysts have set, the stock logically needs to grow 5.99 percent from here. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $31.00, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $82.00.
Outstanding shares total 18.79M with insiders holding 29.93% of the shares and institutional holders owning 30.92% of the company’s common stock. The company has a return on equity of -89.40%. The forward price to earnings ratio is 213.10. The beta has a value of 3.29. Price to book ratio is 12.61 and price to sales ratio is 126.91.
According to a U.S. Securities and Exchange Commission filing, ARK Genomic Revolution ETF has added its position in Arcturus Therapeutics Holdings Inc. (ARCT) to 2,035,282 shares, mirroring a recent increase by 0.33%. ARK Genomic Revolution ETF added 6642.0 shares of Arcturus Therapeutics Holdings Inc. common stock bringing its total worth to about $106.3 million at the end of recent close, SEC documents show. ARK Genomic Revolution ETF isn’t the only investment manager who changed stakes and is followed by Fidelity Select Port – Biotechno, which sold off 0.0 shares to end up with 675,000 shares worth $35.26 million.